We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

234 hedge funds and large institutions have $1.87B invested in BioCryst Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 76 increasing their positions, 59 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

201% more call options, than puts

Call options by funds: $54.3M | Put options by funds: $18M

62% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 26

29% more repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 59

17% more capital invested

Capital invested by funds: $1.61B → $1.87B (+$267M)

6% more funds holding

Funds holding: 221 → 234 (+13)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

1.9% less ownership

Funds ownership: 81.83% → 79.93% (-1.9%)

Holders
234
Holders Change
+13
Holders Change %
+5.88%
% of All Funds
4.03%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
42
Increased
76
Reduced
59
Closed
26
Calls
$54.3M
Puts
$18M
Net Calls
+$36.2M
Net Calls Change
+$11.7M

Top Buyers

1
ACA
Avoro Capital Advisors
New York
+$32.8M
2
GKIM
GW&K Investment Management
Massachusetts
+$18.2M
3
Two Sigma Investments
Two Sigma Investments
New York
+$10.1M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.68M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$6.38M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$44.6M
2
State Street
State Street
Massachusetts
-$20.6M
3
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$15.9M
4
Victory Capital Management
Victory Capital Management
Texas
-$13.4M
5
Norges Bank
Norges Bank
Norway
-$11.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$174M +$366K +28,439 +0.2%
BlackRock
2
BlackRock
New York
$174M -$2.73M -212,423 -2%
BBA
3
Baker Bros. Advisors
New York
$160M – – –
State Street
4
State Street
Massachusetts
$118M -$20.6M -1,600,556 -15%
ACA
5
Avoro Capital Advisors
New York
$114M +$32.8M +2,550,000 +39%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$71.9M +$6.68M +519,290 +10%
Fisher Asset Management
7
Fisher Asset Management
Washington
$65.1M -$682K -52,984 -1%
PAMS
8
Pictet Asset Management (Switzerland)
Switzerland
$60.7M -$15.9M -1,233,189 -20%
RM
9
RP Management
New York
$48.5M – – –
Victory Capital Management
10
Victory Capital Management
Texas
$44.4M -$13.4M -1,044,699 -23%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$42.4M +$1.08M +83,687 +3%
Artisan Partners
12
Artisan Partners
Wisconsin
$33.4M -$3.44M -267,593 -9%
Assenagon Asset Management
13
Assenagon Asset Management
Luxembourg
$33M -$7.23M -561,714 -18%
FFM
14
Fairmount Funds Management
Pennsylvania
$32M -$10.3M -800,000 -24%
BNP Paribas Asset Management
15
BNP Paribas Asset Management
France
$28.7M +$2.34M +181,626 +9%
PHS
16
PFM Health Sciences
California
$27.2M – – –
Two Sigma Advisers
17
Two Sigma Advisers
New York
$25.4M -$870K -67,600 -3%
N
18
Nuveen
North Carolina
$24M -$296K -23,013 -1%
Stifel Financial
19
Stifel Financial
Missouri
$23.3M -$49.5K -3,850 -0.2%
First Manhattan
20
First Manhattan
New York
$22.7M – – –
Northern Trust
21
Northern Trust
Illinois
$22.6M -$259K -20,093 -1%
RSCM
22
Rock Springs Capital Management
Maryland
$21.6M +$3.24M +251,416 +17%
SBH
23
Segall Bryant & Hamill
Illinois
$21.2M -$1.83M -142,020 -8%
Goldman Sachs
24
Goldman Sachs
New York
$18.5M +$1.19M +92,443 +7%
Alkeon Capital Management
25
Alkeon Capital Management
New York
$18.5M +$3.82M +296,940 +25%
1
2 3 4 5

BCRX Hedge Fund Activity: Q3 2022 in Review

234 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2022, worth a combined $1.87B — up 17% from $1.61B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new BCRX positions and 26 closed out — a net gain of 16 holders — while 76 added to existing stakes and 59 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $32.8M. The largest seller was Morgan Stanley, cutting an estimated $44.6M.

  • 234 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2022, up from 221 in Q2 2022.
  • Funds reported $1.87B of BioCryst Pharmaceuticals stock for Q3 2022, up 17% quarter-over-quarter.
  • 42 funds opened new BioCryst Pharmaceuticals positions in Q3 2022 and 26 closed out, a net change of +16 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2022 was Avoro Capital Advisors, an estimated $32.8M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2022 was Morgan Stanley, an estimated $44.6M sold.

Based on aggregated 13F filings for Q3 2022.